These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 38007714

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
    Riccobene TA, Khariton T, Knebel W, Das S, Li J, Jandourek A, Carrothers TJ, Bradley JS.
    J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
    Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.
    Antimicrob Agents Chemother; 2014 Mar; 58(2):885-91. PubMed ID: 24277021
    [Abstract] [Full Text] [Related]

  • 6. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R, Almutairi M, Alm RA, Lahiri SD, San Martin M, Chen A, Ambler JE.
    J Antimicrob Chemother; 2017 Oct 01; 72(10):2796-2803. PubMed ID: 29091195
    [Abstract] [Full Text] [Related]

  • 7. Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil.
    Matzneller P, Lackner E, Lagler H, Wulkersdorfer B, Österreicher Z, Zeitlinger M.
    Antimicrob Agents Chemother; 2016 Jun 01; 60(6):3617-25. PubMed ID: 27044549
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Noel AR, Tomaselli S, Bowker KE.
    Antimicrob Agents Chemother; 2013 Jun 01; 57(6):2451-6. PubMed ID: 23459495
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h.
    Cheng K, Pypstra R, Yan JL, Hammond J.
    J Antimicrob Chemother; 2019 Apr 01; 74(4):1086-1091. PubMed ID: 30597021
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A, Isla A, Rodríguez-Gascón A.
    Int J Antimicrob Agents; 2015 Apr 01; 45(4):399-405. PubMed ID: 25700566
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic and Pharmacodynamic Analyses of Ceftaroline in Adults with Cystic Fibrosis.
    Autry EB, Rybak JM, Leung NR, Gardner BM, Burgess DR, Anstead MI, Kuhn RJ.
    Pharmacotherapy; 2016 Jan 01; 36(1):13-8. PubMed ID: 26748559
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.
    Biek D, Critchley IA, Riccobene TA, Thye DA.
    J Antimicrob Chemother; 2010 Nov 01; 65 Suppl 4():iv9-16. PubMed ID: 21115457
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.
    Riccobene TA, Pushkin R, Jandourek A, Knebel W, Khariton T.
    Antimicrob Agents Chemother; 2016 Oct 01; 60(10):5849-57. PubMed ID: 27431215
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
    Bhavnani SM, Trang M, Griffith DC, Lomovskaya O, Hammel JP, Loutit JS, Cammarata SK, Dudley MN, Ambrose PG, Rubino CM.
    Antimicrob Agents Chemother; 2022 Dec 20; 66(12):e0213021. PubMed ID: 36374023
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
    da Costa TM, Cuba GT, Morgado PGM, Nicolau DP, Nouér SA, Dos Santos KRN, Kiffer CRV.
    BMC Infect Dis; 2020 Jan 23; 20(1):74. PubMed ID: 31973753
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.